<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230954</url>
  </required_header>
  <id_info>
    <org_study_id>IST-67-MCI-1001</org_study_id>
    <nct_id>NCT04230954</nct_id>
  </id_info>
  <brief_title>Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer</brief_title>
  <official_title>A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Alabama</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug: Cabozantinib Drug: Pembrolizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, single arm, open label trial to evaluate the efficacy and
      safety of Cabozantinib (XL184) plus Pembrolizumab in recurrent, persistent and/or metastatic
      cervical cancer with PD-L1 tumor positivity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 16, 2020</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Six months progression free survival as defined by RECIST v1.1 measured from signed written consent to the date of first documented tumor progression using RECIST v1.1, or death due to any cause or 24 months after the end of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Overall response defined by Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Overall survival will be defined as the time from signed written consent to the date of death or 24 months after the end of study treatment. A patient who has not died will be censored at the last known date of contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Emergent Adverse Events</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Evaluate the safety and tolerability measured by incidence of adverse events and serious adverse events, deaths, and laboratory abnormalities as measured by Common Terminology Criteria for Adverse Events v.4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical Cancer Quality of Life</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Quality of life as assessed by FACT Cx quality of life questionnaire. This frequency questionnaire is scaled from 0-4 with 0 being not at all and 4 being very much.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Recurrent Cervical Cancer</condition>
  <condition>Metastatic Cervical Cancer</condition>
  <condition>Persistent Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cabozantinib (XL 184) Plus Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Phase II Study of Cabozantinib (XL 184)Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib 40 MG oral once a day</intervention_name>
    <description>Cabozantinib 40 mg oral once a day</description>
    <arm_group_label>Cabozantinib (XL 184) Plus Pembrolizumab</arm_group_label>
    <other_name>Cabometyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 200 mg IV every 3 weeks</intervention_name>
    <description>Pembrolizumab 200 mg IV every 3 weeks</description>
    <arm_group_label>Cabozantinib (XL 184) Plus Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent or persistent cervical cancer after prior systemic chemotherapy for which
             there is no curative intent option

          -  Documented histologic cervical cancer (acceptable histologies: squamous carcinoma,
             adenocarcinoma, and adenosquamous carcinoma)

          -  Patients must have PD-L1 tumor positivity as defined as CPS&gt;/= 1

          -  Age greater than 18 and ECOG performance status of &lt;= 2

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Prior treatment with cabozantinib or pembrolizumab

          -  Receipt of any type of small molecule kinase inhibitor

          -  Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy

          -  Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy
             within 4 weeks before first dose of study treatment

          -  Known brain metastases or cranial epidural disease unless adequately treated with
             radiotherapy and/or surgery

          -  Anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa
             inhibitors) or platelet inhibitors (eg, clopidogrel)

          -  Uncontrolled, significant intercurrent or recent illness including, but not limited
             to, the following conditions: Cardiovascular disorders: Congestive heart failure New
             York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac
             arrhythmias Uncontrolled hypertension despite optimal antihypertensive treatment,
             stroke

          -  Gastrointestinal (GI) disorders including those associated with a high risk of
             perforation or fistula formation

          -  Clinically significant hematuria, hematemesis, or hemoptysis of &gt; 0.5 teaspoon (2.5
             ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage)
             within 12 weeks before first dose

          -  Active autoimmune disease requiring systemic therapy within the past 2 years

          -  Active infection requiring systemic therapy within the past month

          -  History of immunodeficiency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodney P Rocconi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Alabama</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Blount, RN, MSN</last_name>
    <phone>251-445-9834</phone>
    <email>wlblount@health.southalabama.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney M Rocconi, M.D.</last_name>
      <phone>251-665-8000</phone>
      <email>rocconi@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Blount, RN, MSN</last_name>
      <phone>2514459834</phone>
      <email>wlblount@health.southalabama.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ, van der Burg SH. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009 Oct 15;15(20):6341-7. doi: 10.1158/1078-0432.CCR-09-1652. Epub 2009 Oct 13.</citation>
    <PMID>19825956</PMID>
  </reference>
  <reference>
    <citation>Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology. 2013 Aug;139(4):513-22. doi: 10.1111/imm.12101.</citation>
    <PMID>23521696</PMID>
  </reference>
  <reference>
    <citation>Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.</citation>
    <PMID>21926191</PMID>
  </reference>
  <reference>
    <citation>Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.</citation>
    <PMID>30943124</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Cervical Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Cervical Carcinoma</keyword>
  <keyword>PD L1 positivity</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Squamous Carcinoma</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Adenosquamous Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

